[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362046-105":59,"doc-detail-362046-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-emerging-role-of-the-cancerous-inhibitor-of-protein-phosphatase-2a-in-pulmonary-diseases","The Emerging Role of the Cancerous Inhibitor of Protein Phosphatase 2A in Pulmonary Diseases","","Promising protein targets are implicated in multiple disease pathways, including immune regulation, cell cycle control, senescence, and DNA repair. The oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) coordinates these cellular behaviors mainly by inhibiting PP2A activity. CIP2A binds PP2A and additional proteins to regulate signaling, is overexpressed in lung cancers, and is linked to poor prognosis, proliferation, and therapy resistance. CIP2A signaling also appears in chronic obstructive pulmonary disease and may influence inflammation and fibrotic responses, including NFκB- and cytokine/TGFβ-mediated pathways. This review examines CIP2A-regulated mechanisms, response processes, CIP2A-dependent pathways, and therapeutic strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-emerging-role-of-the-cancerous-inhibitor-of-protein-phosphatase-2a-in-pulmonary-diseases/362046/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-emerging-role-of-the-cancerous-inhibitor-of-protein-phosphatase-2a-in-pulmonary-diseases/362046.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is CIP2A and how does it influence PP2A activity in disease pathways?","Question",{"text":113,"@type":114},"CIP2A is an oncoprotein that inhibits the serine/threonine phosphatase PP2A. By interacting with PP2A and other proteins, it coordinates immune regulation, cell cycle changes, senescence, and DNA repair-related signaling.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is CIP2A linked to lung cancer outcomes?",{"text":118,"@type":114},"CIP2A is overexpressed in non-small cell and small cell lung cancers. Higher CIP2A expression correlates with poor prognosis, increased tumor proliferation, and resistance to targeted therapies or chemotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"In what non-cancer pulmonary diseases is CIP2A signaling observed, and what might it affect?",{"text":122,"@type":114},"CIP2A expression or signaling is reported in chronic obstructive pulmonary disease, and recently in a bronchiolitis obliterans model. The review also connects CIP2A to inflammation and possibly fibrotic responses through NFκB activation and cytokine/TGFβ signaling.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},362046,1790610084,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nThe Emerging Role of the Cancerous Inhibitor of Protein Phosphatase 2A in Pulmonary Diseases  \nHamza Hamza 1, Dinesh Nirmal 1, Stephanie Pappas 1, Ugochukwu Ebubechukwu 1, Sunydip Gill 1, Adam Al-Ajam 1, Michael Ohlmeyer 2 and Patrick Geraghty 1, *  \nAcademic Editor: Selvakumar Subbian  \nReceived: 12 August 2025  \nRevised: 16 September 2025  \nAccepted: 19 September 2025  \nPublished: 25 September 2025  \nCitation: Hamza, H.; Nirmal, D.; Pappas, S.; Ebubechukwu, U.; Gill, S.; Al-Ajam, A.; Ohlmeyer, M.; Geraghty, P. The Emerging Role of the Cancerous Inhibitor of Protein Phosphatase 2A in Pulmonary Diseases. Medicina 2025, 61, 1740. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)[10.3390/medicina61101740](10.3390/medicina61101740)  \n[Copyright:](Copyright:) © 2025 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Medicine, Downstate Health Sciences University, State University of New York,  \n450 Clarkson Avenue, Brooklyn, NY 11203, USA; [hamza.hamza@downstate.edu](hamza.hamza@downstate.edu) (H.H.); [dinesh.nirmal@downstate.edu](dinesh.nirmal@downstate.edu) (D.N.); [stephanie.pappas@downstate.edu](stephanie.pappas@downstate.edu) (S.P.); [ugochukwu.ebubechukwu@downstate.edu](ugochukwu.ebubechukwu@downstate.edu) (U.E.); [sunydip.gill@downstate.edu](sunydip.gill@downstate.edu) (S.G.); [adjam800@gmail.com](adjam800@gmail.com) (A.A.-A.)  \n2 Atux Iskay LLC, Plainsboro, NJ 08536, USA; [michael.ohlmeyer@gmail.com](michael.ohlmeyer@gmail.com)  \n* [Correspondence: patrick.geraghty@downstate.edu](Correspondence: patrick.geraghty@downstate.edu); Tel.: +1-718-270-3141  \nAbstract  \nPromising protein targets are observed to play a role in multiple pathways across a variety of diseases, such as the regulation of immune responses, cell cycle, senescence, and DNA repair. The oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) can coordinate all these cell characteristics predominately by inhibiting the activity of the serine threonine protein phosphatase 2A (PP2A) . CIP2A directly interacts with PP2A and other proteins, such as the DNA damage protein topoisomerase II-binding protein 1, to regulate signal transduction. CIP2A is overexpressed in many human cancers, including small and non-small cell lung cancers. High CIP2A expression in lung cancer correlates with poor prognosis, increased tumor proliferation, and resistance to targeted therapies or chemotherapy. Interestingly, CIP2A expression or signaling is also observed in several non-cancerous pulmonary diseases, such as chronic obstructive pulmonary disease. CIP2A can determine whether DNA-damaged cells enter mitosis and can mediate whether DNA repair occurs. CIP2A is also a regulator of inflammation and possibly fibrotic responses. Its functions are linked to altered NFκB activation and TNFα, IL-1β, IL-4, IL-6, IL-10, IL-13, and TGFβ signaling. This review outlines the possible impact of CIP2A-mediated signaling in pulmonary diseases, the processes that regulate CIP2A responses, CIP2A-dependent pathways, and potential therapeutic strategies targeting CIP2A. Substantial medicinal chemistry efforts are underway to develop therapeutics aimed at modulating CIP2A activity. The development of specific inhibitors of CIP2A that selectively target its expression or protein stability could improve our understanding of CIP2A’s function in pulmonary diseases.  \nKeywords: cancerous inhibitor of PP2A; protein phosphatase 2A; pulmonary diseases; immune responses; cell cycle; signaling transduction  \n1. Introduction  \nCancerous inhibitor of PP2A (CIP2A) is an oncoprotein that is well documented a","cbCaitM5RL1ZGaqv","https://ap.wps.com/l/cbCaitM5RL1ZGaqv","pdf",594839,25,"English","# Introduction\n## Global Impact of Respiratory Diseases","[{\"question\":\"What is CIP2A and how does it influence PP2A activity in disease pathways?\",\"answer\":\"CIP2A is an oncoprotein that inhibits the serine/threonine phosphatase PP2A. By interacting with PP2A and other proteins, it coordinates immune regulation, cell cycle changes, senescence, and DNA repair-related signaling.\"},{\"question\":\"How is CIP2A linked to lung cancer outcomes?\",\"answer\":\"CIP2A is overexpressed in non-small cell and small cell lung cancers. Higher CIP2A expression correlates with poor prognosis, increased tumor proliferation, and resistance to targeted therapies or chemotherapy.\"},{\"question\":\"In what non-cancer pulmonary diseases is CIP2A signaling observed, and what might it affect?\",\"answer\":\"CIP2A expression or signaling is reported in chronic obstructive pulmonary disease, and recently in a bronchiolitis obliterans model. The review also connects CIP2A to inflammation and possibly fibrotic responses through NFκB activation and cytokine/TGFβ signaling.\"}]","The Emerging Role of the Cancerous Inhibitor of Protein Phosphatase 2A in Pulmonary Diseases | PDF",1790146341,63,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6677aa3d2de3202ee9f0c86b5b5910f.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af3538acf649e2c5a75695a1fc67df08.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6c91ecf716c961636003c43bb84a434.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e716d5f3106b40780f3fc42f23e11939.webp",980,1385]